Psychopharmacology

In this CME article, familiarize yourself with various pharmacokinetic, pharmacodynamic, and patient-specific factors to review to develop a successful cross-titration plan from one antipsychotic to another.

SrLCs include sexual dysfunction and special considerations for pediatric and geriatric populations.

OCD is highly comorbid and warrants consideration in difficult to treat cases. Learn more here.

Put treatment resistance in perspective with Sheldon H. Preskorn, MD.

Psychiatric Times featured a wide variety of psychiatric issues in this year’s CMEs.

Caplyta is now FDA-approved for depressive episodes from bipolar I and II.

The importance of specifically defining a drug’s mechanism as partial agonism or antagonism/partial agonism for better clinical outcomes.

Some psychiatric medications that can trigger Torsades de Pointes (TdP), a potentially fatal polymorphic ventricular tachycardia that arises during abnormal ventricular repolarization. Are you aware of the risk factors that increase risk of TdP?

Microdosing at “Tranquillum House,” and its implications for real-world experimental psychopharmacology.

Results suggest that psilocybin therapy may prove to be helpful in improving quality of life for patients with cancer.

What is the real-world clinical efficacy of SSRIs and other antidepressant medications compared to RCT placebos?

New Drug Application to be submitted for MDD in late 2022, with separate filing for PPD planned for early 2023. 

The history of medicine is a never-ending work in progress. What is the next chapter in the psychiatry and genetics story?

Sheldon Preskorn, MD, shares insights into drug mechanisms and delivery to better help patients with major depressive disorder.

Bringing science to the practice of psychiatry has been the personal goal of Sheldon H. Preskorn, MD—the Educator of the Year.

Modifications to the Clozapine Risk Evaluation and Mitigation Strategy go into effect November 15, 2021. Are you up to date?

At the Annual Psychiatric Times World CME Conference, an all-star lineup of presenters will share their latest research. Check out this preview of the full agenda.

A hypnotic might be a good option for augmenting depression treatment, but which hypnotic has the best evidence for efficacy?

After a string of disappointing results, mirtazapine gets another look in a recent study.

A deep dive into the history, side effects, and efficacy of a controversial drug.

Why does the prospect of getting back to normal after the pandemic disturb some patients? And what can be done to overcome these fears?

Although the new drug aducanumab has grabbed all the headlines, the future of Alzheimer treatment may be just as much about public health campaigns as it is about psychopharmacology. In this episode of Psych Pearls, we find out why.

A rare robust finding from a study on bipolar depression.

Travelling the middle road between skepticism and scientism in psychiatric research and treatment.

Patients with intellectual or developmental disabilities need psychiatrists to learn some special skills.